x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011877
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG1 |
| Host Species | Mouse |
| Reactivity | Human, Mouse, Rat, Monkey |
| Applications | WB, IF |
| Product Description | Monoclonal antibody is produced by immunizing animals with a recombinant protein specific to the carboxy terminus of human calumenin protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | CALU |
| UniProt No. | O43852 |
| Gene ID | 813 |
| Gene Description | Calumenin belongs to the CREC family of proteins that also contains reticulocalbin, ERC-55/TCBP-49/E6BP, Cab45, and crocalbin/CBP-50. These EF-hand proteins localize to the endoplasmic reticulum and are involved in the secretory pathway in mammalian cells. Calumenin exists as two isoforms corresponding to alternativly spliced variants of the CALU gene. Calumenin has been shown to localize to the ER via a carboxy terminal HDEF ER retention signal, and undergoes secretion after trafficking through the secretory pathway. Secreted calumenin plays a role in amyloidosis by interacting with serum amyloid P component. Calumenin is also a chaperone for mutants of the cystic fibrosis transmembrane conductance regulator. Researchers performing a proteomics analysis of endometrial cancer identified calumenin as a potential target for endometrial carcinoma. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
